Literature DB >> 27458221

Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection.

Beatriz E Ferro1, Shashikant Srivastava2, Devyani Deshpande2, Jotam G Pasipanodya2, Dick van Soolingen3, Johan W Mouton4, Jakko van Ingen1, Tawanda Gumbo5.   

Abstract

In a hollow-fiber model, we mimicked the drug exposures achieved in the lungs of humans treated with standard amikacin, clarithromycin, and cefoxitin combination therapy for Mycobacterium abscessus infection. At optimal dosing, a kill rate of -0.09 (95% confidence interval, -0.04 to 0.03) log10 CFU per ml/day was achieved over the first 14 days, after which there was regrowth due to acquired drug resistance. Thus, the standard regimen quickly failed. A new regimen is needed.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27458221      PMCID： PMC5038227          DOI： 10.1128/AAC.00990-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Biological variability and the emergence of multidrug-resistant tuberculosis.

Authors:  Tawanda Gumbo
Journal:  Nat Genet       Date:  2013-07       Impact factor: 38.330

Review 2.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

3.  Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease.

Authors:  Beatriz E Ferro; Shashikant Srivastava; Devyani Deshpande; Jotam G Pasipanodya; Dick van Soolingen; Johan W Mouton; Jakko van Ingen; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

4.  In vivo evaluation of antibiotic activity against Mycobacterium abscessus.

Authors:  Isabelle Lerat; Emmanuelle Cambau; Romain Roth Dit Bettoni; Jean-Louis Gaillard; Vincent Jarlier; Chantal Truffot; Nicolas Veziris
Journal:  J Infect Dis       Date:  2013-11-18       Impact factor: 5.226

5.  Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing.

Authors:  Sylvaine Bastian; Nicolas Veziris; Anne-Laure Roux; Florence Brossier; Jean-Louis Gaillard; Vincent Jarlier; Emmanuelle Cambau
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

6.  Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.

Authors:  Shashikant Srivastava; Jotam G Pasipanodya; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  J Infect Dis       Date:  2011-10-21       Impact factor: 5.226

7.  Bronchial secretion levels of amikacin.

Authors:  W L Dull; M R Alexander; J E Kasik
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

8.  Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.

Authors:  Beatriz E Ferro; Shashikant Srivastava; Devyani Deshpande; Jotam G Pasipanodya; Dick van Soolingen; Johan W Mouton; Jakko van Ingen; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

9.  Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model.

Authors:  Beatriz E Ferro; Shashikant Srivastava; Devyani Deshpande; Carleton M Sherman; Jotam G Pasipanodya; Dick van Soolingen; Johan W Mouton; Jakko van Ingen; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

10.  Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections.

Authors:  Richard J Wallace; Gary Dukart; Barbara A Brown-Elliott; David E Griffith; Ernesto G Scerpella; Bonnie Marshall
Journal:  J Antimicrob Chemother       Date:  2014-03-14       Impact factor: 5.790
View more
  22 in total

1.  Preclinical Pharmacokinetic and Pharmacodynamic Data To Support Cefoxitin Nebulization for the Treatment of Mycobacterium abscessus.

Authors:  Shachi Mehta; Vincent Aranzana-Climent; Blandine Rammaert; Nicolas Grégoire; Sandrine Marchand; William Couet; Julien M Buyck
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

2.  Clofazimine for the Treatment of Mycobacterium kansasii.

Authors:  Shashikant Srivastava; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

3.  Bedaquiline Inhibits the ATP Synthase in Mycobacterium abscessus and Is Effective in Infected Zebrafish.

Authors:  Christian Dupont; Albertus Viljoen; Sangeeta Thomas; Françoise Roquet-Banères; Jean-Louis Herrmann; Kevin Pethe; Laurent Kremer
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

4.  Biofilms of Mycobacterium abscessus Complex Can Be Sensitized to Antibiotics by Disaggregation and Oxygenation.

Authors:  Mette Kolpen; Peter Østrup Jensen; Tavs Qvist; Kasper Nørskov Kragh; Cecillie Ravnholt; Blaine Gabriel Fritz; Ulla Rydahl Johansen; Thomas Bjarnsholt; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

5.  Successful Systemic and Topical Treatment of Mycobacterium abscessus Otomastoiditis.

Authors:  Floor van Wijk; Jérôme Waterval; Koen van Aerde; Stefanie S V Henriet; F J Anton Meijer; Lennaert C Borra; Rob E Aarnoutse; Jakko van Ingen
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

6.  Efficacy of Bedaquiline, Alone or in Combination with Imipenem, against Mycobacterium abscessus in C3HeB/FeJ Mice.

Authors:  Vincent Le Moigne; Clément Raynaud; Flavie Moreau; Christian Dupont; Jérôme Nigou; Olivier Neyrolles; Laurent Kremer; Jean-Louis Herrmann
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

7.  Mutations in the MAB_2299c TetR Regulator Confer Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus.

Authors:  Matthias Richard; Ana Victoria Gutiérrez; Albertus Viljoen; Daniela Rodriguez-Rincon; Françoise Roquet-Baneres; Mickael Blaise; Isobel Everall; Julian Parkhill; R Andres Floto; Laurent Kremer
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

8.  Anti-Mycobacterium abscessus Activity of Tuberculosis F-ATP Synthase Inhibitor GaMF1.

Authors:  Priya Ragunathan; Thomas Dick; Gerhard Grüber
Journal:  Antimicrob Agents Chemother       Date:  2022-04-28       Impact factor: 5.191

9.  Evidence for Inhibition of Topoisomerase 1A by Gold(III) Macrocycles and Chelates Targeting Mycobacterium tuberculosis and Mycobacterium abscessus.

Authors:  Rashmi Gupta; Carolina Rodrigues Felix; Matthew P Akerman; Kate J Akerman; Cathryn A Slabber; Wenjie Wang; Jessie Adams; Lindsey N Shaw; Yuk-Ching Tse-Dinh; Orde Q Munro; Kyle H Rohde
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

Review 10.  Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections.

Authors:  Jan-Willem Alffenaar; Anne-Grete Märtson; Scott K Heysell; Jin-Gun Cho; Asad Patanwala; Gina Burch; Hannah Y Kim; Marieke G G Sturkenboom; Anthony Byrne; Debbie Marriott; Indy Sandaradura; Simon Tiberi; Vitali Sintchencko; Shashikant Srivastava; Charles A Peloquin
Journal:  Clin Pharmacokinet       Date:  2021-03-10       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.